RemeGen Yönetim
Yönetim kriter kontrolleri 3/4
RemeGen's CEO is Jianmin Fang, appointed in Oct 2008, has a tenure of 16.08 years. total yearly compensation is CN¥14.66M, comprised of 37% salary and 63% bonuses, including company stock and options. directly owns 11.44% of the company’s shares, worth HK$2.01B. The average tenure of the management team and the board of directors is 2.8 years and 4.5 years respectively.
Anahtar bilgiler
Jianmin Fang
İcra Kurulu Başkanı
CN¥14.7m
Toplam tazminat
| CEO maaş yüzdesi | 37.0% |
| CEO görev süresi | 16.1yrs |
| CEO sahipliği | 11.4% |
| Yönetim ortalama görev süresi | 2.8yrs |
| Yönetim Kurulu ortalama görev süresi | 4.5yrs |
Son yönetim güncellemeleri
Recent updates
Improved Revenues Required Before RemeGen Co., Ltd. (HKG:9995) Stock's 31% Jump Looks Justified
Sep 28
RemeGen Co., Ltd. (HKG:9995) Just Reported Earnings, And Analysts Cut Their Target Price
Aug 20Benign Growth For RemeGen Co., Ltd. (HKG:9995) Underpins Stock's 41% Plummet
Jul 22Here's Why Shareholders May Want To Be Cautious With Increasing RemeGen Co., Ltd.'s (HKG:9995) CEO Pay Packet
Jun 21RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up
Apr 04Is RemeGen (HKG:9995) Using Debt In A Risky Way?
Mar 24RemeGen Co., Ltd. (HKG:9995) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Feb 18Getting In Cheap On RemeGen Co., Ltd. (HKG:9995) Is Unlikely
Dec 29RemeGen Co., Ltd. (HKG:9995) Shares Could Be 34% Below Their Intrinsic Value Estimate
Oct 16Is RemeGen (HKG:9995) In A Good Position To Invest In Growth?
Aug 03Is There An Opportunity With RemeGen Co., Ltd.'s (HKG:9995) 35% Undervaluation?
Jun 22RemeGen Co., Ltd. (HKG:9995) Investors Are Less Pessimistic Than Expected
May 10Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 36%?
Mar 09RemeGen's (HKG:9995) Earnings Aren't As Good As They Appear
May 04RemeGen Co., Ltd. (HKG:9995) Analysts Just Cut Their EPS Forecasts Substantially
Apr 08RemeGen Co., Ltd. (HKG:9995) Just Reported And Analysts Have Been Cutting Their Estimates
Feb 23We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely
Jan 21Are Investors Undervaluing RemeGen Co., Ltd. (HKG:9995) By 42%?
Nov 30We're Hopeful That RemeGen (HKG:9995) Will Use Its Cash Wisely
Oct 16A Look At The Intrinsic Value Of RemeGen Co., Ltd. (HKG:9995)
Aug 24CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CN¥2b |
| Jun 30 2024 | n/a | n/a | -CN¥2b |
| Mar 31 2024 | n/a | n/a | -CN¥2b |
| Dec 31 2023 | CN¥15m | CN¥5m | -CN¥2b |
| Sep 30 2023 | n/a | n/a | -CN¥1b |
| Jun 30 2023 | n/a | n/a | -CN¥1b |
| Mar 31 2023 | n/a | n/a | -CN¥1b |
| Dec 31 2022 | CN¥27m | CN¥5m | -CN¥999m |
| Sep 30 2022 | n/a | n/a | CN¥276m |
| Jun 30 2022 | n/a | n/a | CN¥231m |
| Mar 31 2022 | n/a | n/a | CN¥174m |
| Dec 31 2021 | CN¥8m | CN¥4m | CN¥276m |
Tazminat ve Piyasa: Jianmin's total compensation ($USD2.07M) is above average for companies of similar size in the Hong Kong market ($USD496.15K).
Tazminat ve Kazançlar: Jianmin's compensation has been consistent with company performance over the past year.
CEO
Jianmin Fang (61 yo)
16.1yrs
Görev süresi
CN¥14,658,000
Tazminat
Dr. Jianmin Fang is Co-Founder at RemeGen Co. Ltd. He has been Director, Chief Executive Officer and GM of RemeGen Co. Ltd. and served as its Chief Scientific Officer since October 16, 2008 to 2023 and red...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 11.1yrs | CN¥15.15m | Veri yok | |
| Co-Founder | 16.1yrs | CN¥14.66m | 11.44% HK$ 2.0b | |
| CFO & Joint Company Secretary | 1.2yrs | CN¥1.25m | Veri yok | |
| Chief Medical Officer | no data | CN¥24.01m | 0.00090% HK$ 157.9k | |
| Executive Director | no data | CN¥1.13m | Veri yok | |
| Chief Operating Officer | no data | Veri yok | Veri yok | |
| Chief Technical Officer | no data | Veri yok | Veri yok | |
| Chief Scientific Officer | no data | Veri yok | Veri yok | |
| Chief Business Officer | less than a year | Veri yok | Veri yok | |
| Chief Manufacturing Officer | no data | Veri yok | Veri yok | |
| Board Secretary | 4.5yrs | Veri yok | Veri yok |
2.8yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim: 9995's management team is considered experienced (2.8 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 11.1yrs | CN¥15.15m | Veri yok | |
| Co-Founder | 16.1yrs | CN¥14.66m | 11.44% HK$ 2.0b | |
| Chief Medical Officer | 4.5yrs | CN¥24.01m | 0.00090% HK$ 157.9k | |
| Executive Director | 16.3yrs | CN¥1.13m | Veri yok | |
| Member of Scientific Advisory Board | no data | CN¥125.00k | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Non-Executive Director | 4.5yrs | Veri yok | Veri yok | |
| Non-Executive Director | 4.5yrs | Veri yok | Veri yok | |
| Independent Non-Executive Director | 4.5yrs | CN¥300.00k | Veri yok | |
| Chairman of the Supervisory Board | 4.5yrs | Veri yok | Veri yok | |
| Independent Non-Executive Director | 3.4yrs | CN¥300.00k | Veri yok | |
| Independent Non-Executive Director | 2.5yrs | CN¥300.00k | Veri yok |
4.5yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: 9995's board of directors are considered experienced (4.5 years average tenure).